title: Cross bonding and stiffening of the red cell membrane.
abstract: Cross bonding and stiffening of the human red cell membrane was studied using treatments with SH, amino, and carboxyl reagents, oxidizing and denaturing treatments and acidification. Membrane cross bonding was initiated when, after red cell treatment, opposite areas of the cytoplasmic face of the red cell membrane were brought into contact by cell shrinking. Membrane cross bonding was detected by light microscopy when this contact persisted upon swelling the cells in a hypotonic medium. Membrane stiffening was recorded as a decrease in elongation of red cells in the shear field of a viscous dextran solution. No correlation was found between membrane cross bonding and membrane stiffening. The results are explained by the existence of two modifications of spectrin, type I causing solely membrane stiffening, type II causing membrane cross bonding as well as membrane stiffening. The amino and carboxyl reagents caused only type I modification. The other treatments caused both types of modification although with varying proportions. The results support the previously suggested mechanism of membrane cross bonding which involves a rearrangement of spectrin similar to denaturation by heat or urea, a decrease in associations within the membrane skeletal network, and a lateral aggregation of membrane proteins. These changes are proposed to occur by the type II modification. The data further substantiate the membrane stiffening effect of inter- and intra-molecular cross linking of spectrin which is identified with the type I modification. Finally, hypotheses are presented concerning the mechanism of membrane stiffening due to type II modifications of spectrin.
authors: Institut für Physiologie, Medizinische Fakultät, Rheinische-Westfälische Technische Hochschule, Aachen, F.R.G.
authors: T M
authors: TM
authors: Fischer
mesh_terms: D003432:Cross-Linking Reagents / Q000494:pharmacology*; D003958:Diamide / Q000494:pharmacology; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000648:ultrastructure*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008315:Malondialdehyde / Q000494:pharmacology; D010084:Oxidation-Reduction; D010659:Phenylhydrazines / Q000494:pharmacology; D011489:Protein Denaturation; D013049:Spectrin / Q000378:metabolism; D013439:Sulfhydryl Reagents / Q000494:pharmacology
chemical_list: D003432:Cross-Linking Reagents; D010659:Phenylhydrazines; D013439:Sulfhydryl Reagents; D003958:Diamide; D013049:Spectrin; D008315:Malondialdehyde; C006384:N(1)-acetylphenylhydrazine